Elutia Inc. recently delivered a presentation at the LD Micro Main Event XIX Conference, highlighting its strategy to replace traditional biologic materials with drug-enhanced biomaterials, initially focusing on breast reconstruction. The company emphasized its validated technology platform, including the development and sale of the first FDA-cleared drug-eluting bioenvelope for pacemakers to Boston Scientific for $88 million. Elutia is now leveraging this technology to address the $1.5 billion breast reconstruction market, where currently one in three patients experiences serious post-operative complications and one in seven faces infection. The company reports having the resources and infrastructure in place to support product clearance and commercialization. You can access the full presentation through the link below.